MUMBAI - In the run up to the annual U.S.-India BioPharma & Healthcare Summit, June 23 in Boston, PharmAsia News sat down with key industry players to discuss the state of the pharma industry in India. In the first part of this series, Boston Consulting Group provided a sneak preview of a report commissioned by the USA-India Chamber of Commerce that will be released at the summit ( 'Sneak Preview: BCG Study Predicts Strong R&D Focus In India; Big Pharma May Leverage India For 'Niche Busters' And Stem Cells,' PharmAsia News, May 23, 2011 ). In the second story, PharmAsia News' India bureau spoke with Biogen Idec SVP Gunther Winkler, who discussed the big biotech's strategy in India and important policy decisions facing the Indian government ( 'Biogen's MS Drugs Ride High In India, Backed By Special Pricing, Awareness Building And Pharmacovigilance,' PharmAsia News, June 13, 20110.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.
Private Company Edition: Six biopharma companies raised venture capital rounds totaling $100m or more in May, matching the number of mega-rounds in April and March. Among other recent financings, Syndeio launched with $90m and SpyGlass raised a $75m series D round.
The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.
